PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 26, 2010
- First proof-of-concept clinical study of ataluren in a metabolic disorder -
Additional Formats
Oct 15, 2010
- 29.7 meter average change in 6-minute walk distance compared to placebo at 48 weeks - - Safety results show ataluren was generally well tolerated - - Data to be the basis of interactions with regulatory authorities -

Additional Formats
Sep 21, 2010
SOUTH PLAINFIELD, NJ – SEPTEMBER 21, 2010 – PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense
Additional Formats
Jun 07, 2010
-Over $100 Million in Cumulative Grant Funding Raised to Date-
Additional Formats
Mar 03, 2010
SOUTH PLAINFIELD, NJ and CAMBRIDGE, MA – March 03, 2010 – PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular
Additional Formats
Jan 19, 2010
- Study funded in part by a grant from the Muscular Dystrophy Association-
Additional Formats